Inhibition of RNF5 can suppress AML cell growth and improve the responsiveness to HDAC inhibitors [29], indicating that RNF5 could act as a candidate target for chemotherapy of leukemia and lymphoma. The gene discussed is RNF5; the disease is lymphoma.